title: Treatment of neurogenic diabetes insipidus.
abstract: Central or neurogenic diabetes insipidus results from a deficiency in antidiuretic hormone (ADH) or arginine-vasopressin (AVP). Treatment is based on replacement therapy with the hormone analog desmopressin (d-DAVP). d-DAVP can be administered subcutaneously to infants or patients with postoperative or posttraumatic brain injury being monitored for transient diabetes insipidus. Intranasal and oral forms are also available. The recently introduced lyophilisate, which melts under the tongue, has replaced the tablet form (recently withdrawn from the market in France) and provides better bioavailability. Irrespective of the mode of administration, it is usually the patient who finds the effective minimal dose necessary for a normal life, i.e. without excessive polyuria, particularly at night. Patient education is necessary to avoid the risk of water intoxication and hyponatremia.
authors.affiliation: Service d'endocrinologie et des maladies de la reproduction, hôpitaux universitaires Paris-Sud, hôpital de Bicêtre, université Paris-Sud 11, Inserm U693, AP-HP, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France. philippe.chanson@bct.ap-hop-paris.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Chanson
authors.forename: Sylvie
authors.initials: S
authors.lastname: Salenave
mesh_terms: D050034:Antidiuretic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy; D002626:Chemistry, Pharmaceutical; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000493:pharmacokinetics; D020790:Diabetes Insipidus, Neurogenic / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D006801:Humans; D007223:Infant
chemical_list: D050034:Antidiuretic Agents; D003894:Deamino Arginine Vasopressin